MeSH tree: C15.604.515.569
The U.S. Environmental Protection Agency (EPA) is proposing to loosen limits on emissions of ethylene oxide, a gas used to sterilize many medical devices that is also linked to cancer.
Mar 16, 2026
0
5
An innovative platform developed by PKU researchers called "cf-EpiTracing" has proved capable of detecting and tracing diseases from as little as 50 μl of human plasma, or roughly a drop of blood. The research, published ...
Mar 16, 2026
0
13
Cancers emerge from many different paths. One path begins early, in embryonic development, when a protein complex called PRC2, which regulates cell differentiation, identity, and plasticity, becomes dysfunctional. PRC2 has ...
Mar 11, 2026
0
10
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from healthy ones. Now, scientists ...
Mar 10, 2026
0
15
A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 in the journal Cell, by ...
Mar 6, 2026
0
16
Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of Rochester's Wilmot Cancer Institute. And he isn't alone: 70% of patients in the trial who had advanced-stage ...
Mar 1, 2026
0
26
The Epstein-Barr virus (EBV) can cause certain types of cancer or autoimmune diseases, but how the body controls this common viral infection is largely unknown. Researchers at the University Hospital Bonn (UKB) and the University ...
Feb 19, 2026
0
14
A new UNC study finds that a chemical derived from ashwagandha disrupts viral and cancer processes that make B-cell lymphomas difficult to treat with standard chemotherapy. Cancer has many causes, including inherited genes, ...
Feb 19, 2026
0
16
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive ...
Feb 9, 2026
0
7
In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat non-Hodgkin lymphomas who received ...
Feb 9, 2026
0
6
